Building World-Class HEOR Teams

Creating Convincing Value Propositions for Payers

Building World-Class HEOR Teams


Make the most of your money, time and effort by advancing your approach to HEOR studies.

  • Demonstrate and communicate the need for HEOR involvement earlier in product development, not just at launch.
  • Improve strategic planning in key facets for HEOR teams: structure, spending, staffing, activities and studies.
  • Prioritize HEOR spending and activities to ensure maximum impact with payers.
  • Description
  • Additional information


This report guides companies in structuring health economics operations at the global and country levels. Data and best practices help teams on the ground focus on working with directly with payers while being supported effectively by global groups.

Building World-Class HEOR Teams: Creating Convincing Value Propositions for Payers

  • Publication Date: March 2015
  • Pages: 169
  • Chapter:s 4
  • Metrics: 500+
  • Charts/Graphics: 118

Data have been split by group type:

  • Central groups
  • Country-level affiliates

Data have also been split by company size and type:

  • Top 10 (12 companies — including 10 country-level groups)
  • Top 50 (14 companies — including 9 country-level groups
  • Small (4 companies)
  • Device (9 companies — including 4 country-level groups)
Report Features

Benchmarks show HEOR spending as well as data comparing health outcomes spending between compounds in development and marketed brands. Furthermore, data show HEOR group oversight, leadership and funding sources. Infographics compare HEOR group structures and processes across company sizes/types and geography, while metrics compare product portfolios with HEOR spending by product type. Charts show HEOR spending allocation on 13 activities, as well as the percentage of HEOR budget spent on core tasks.

Reasons to Buy

Use the right HEOR studies to build understanding of what is driving patient needs — and to address payer requirements: Getting an early start on developing the health economics plan for a product is crucial in meeting payer needs. Identifying comparators and understanding the competitive landscape at launch can be difficult in early phases — but groups are still able to conduct research that lays the groundwork for a product’s future success on the market. Once launch approaches and health economics and outcomes research involvement reaches its peak, companies should know how many studies are required to support a product effectively, as well as the potential budgetary pressures that come with addressing payer concerns. This report guides companies in making critical decisions and planning surrounding HEOR studies and their costs. Benchmarks include how many health economics studies are conducted and their cost and duration.

Target Audience

HEOR groups are the main audience for this research, along with any teams involved in managed markets, payer relationships, pricing & reimbursement. That means that health economics managers, directors, VPs, as well as managed markets account managers and health economists, stand to benefit from the findings and metrics in this report.

Chapter Example

When it comes to meeting payer needs from a health economics perspective, pharmaceutical companies are under increasing pressure to provide a full value story to payers that answers outcomes, pharmacoeconomic and even budgetary questions. Stakeholders, including payers, physicians, and even patients in many markets, now expect to see a pharmacoeconomic case for the use of a new product. These demands place a growing burden on the health economics groups responsible for generating these data. They also present a challenge in communicating these findings to payers successfully. This report serves as a guide for structuring health economics operations at the global and country levels. Its data and best practices will help teams on the ground focus on working with directly with payers while being effectively supported by global groups.